Genetic Signatures

Genetic Signatures EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Genetic Signatures (GSS.AX) as of Oct 29, 2026 is -46.14 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -33.83 % — a change of 36.38% (lower).

EBIT/Assets

-46.14 %

YoY

36.38%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Genetic Signatures is 2026 -46.14 % . Operating Income to Assets Ratio (EBIT/Assets) of Genetic Signatures was 2025 -33.83 % . It decreases by 36.38% lower compared to the previous year.

The Genetic Signatures EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2019
-29.67 AUD
Jan 1, 2020
-9.72 AUD
Jan 1, 2021
2.88 AUD
Jan 1, 2022
4.97 AUD
Jan 1, 2023
-38.49 AUD
Jan 1, 2024
-33.19 AUD
Jan 1, 2025
-33.83 AUD
Jan 1, 2026
-46.14 AUD
The Genetic Signatures EBIT/Assets history
YEAREBIT/AssetsYoY
-46.14 %+36.38%
-33.83 %+1.92%
-33.19 %-13.77%
-38.49 %-873.91%
4.97 %+72.65%
2.88 %-129.65%
-9.72 %-67.26%
-29.67 %+27.55%
-23.26 %+47.73%
-15.75 %-68.68%
-50.27 %+26.23%
-39.83 %+433.72%
-7.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genetic Signatures stock

Operating Income to Assets Ratio (EBIT/Assets) of Genetic Signatures is -46.14 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of Genetic Signatures changed from -33.83 % to -46.14 %, representing a 36.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Genetic Signatures with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Genetic Signatures

All Key Metrics — Genetic Signatures